Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Evercore ISI Group Upgrades Akero Therapeutics to Outperform, Raises Price Target to $50

Evercore ISI Group analyst Liisa Bayko upgrades Akero Therapeutics (NASDAQ:AKRO) from In-Line to Outperform and raises the price target from $10 to $50.
byBenzinga Newsdesk
September 14, 2022
1 minute read
Total
0
Shares
0
0
0
0
0
0

Evercore ISI Group analyst Liisa Bayko upgrades Akero Therapeutics (NASDAQ:AKRO) from In-Line to Outperform and raises the price target from $10 to $50.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts